Gene analysis points to possible cuproptosis-immune link in unexplained infertility

Unexplained infertility describes cases in which a couple does not conceive after at least a year of trying, yet routine assessments find normal ovulation, open fallopian tubes and no major semen abnormality. One possible source of the problem is the endometrium, the lining of the uterus that must become receptive for an embryo to implant.

A study published in Reproductive and Developmental Medicine explores whether genes associated with cuproptosis may be connected to changes in this tissue. Cuproptosis is a recently identified form of regulated cell death. It occurs when excess copper disrupts proteins involved in mitochondrial energy production, creating stress that can damage or kill the cell. Its possible role in unexplained infertility has received little attention.

The researchers used a public dataset containing gene-expression measurements from endometrial samples of 24 women with unexplained infertility, 24 healthy women of reproductive age and 24 women with recurrent miscarriage. The main comparison between the unexplained-infertility and healthy-control groups examined 27 cuproptosis-related genes (CRGs).

Seven of these genes differed between the two groups. Computer-based estimates of the samples’ immune composition also suggested that women with unexplained infertility had higher infiltration by several immune-cell types, including natural killer cells, dendritic cells, mast cells and CD4-positive T cells. Some immune patterns were correlated with CRG expression, pointing to a possible connection between copper-related cellular stress and the local immune environment. However, the analysis cannot determine whether the gene changes cause immune alterations or infertility.

The findings suggest that unexplained infertility may include biologically distinct endometrial patterns and that copper-related cellular processes could provide a new direction for studying its relationship with local immune activity. The identified genes may eventually help researchers classify patients more precisely, but the model is not ready for clinical diagnosis or treatment decisions.

“Additional clinical or in vitro experimental evaluations are needed to validate the expression levels of CRGs,” the authors note.

Larger, independent patient groups and laboratory studies will be needed to confirm the molecular clusters, test whether cuproptosis directly influences the endometrial immune environment and determine whether the candidate genes have meaningful clinical value.